Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study will be conducted at Rigshospitalet in Copenhagen, Denmark, and will enroll up to 39 patients. Participants will be prospectively selected based on PTGR1 overexpression and DNA-damage-repair deficiency, marking a significant step in the company's precision oncology approach.
The trial aims to evaluate LP-184 in patients who have progressed on or are ineligible for current standard-of-care therapies. This patient population represents a high unmet medical need, as bladder cancer often becomes resistant to existing treatments. By leveraging its proprietary RADR platform, Lantern Pharma seeks to identify patients most likely to benefit from LP-184, potentially improving outcomes and reducing unnecessary side effects.
LP-184 is an acylfulvene compound that targets DNA damage repair pathways. The drug has shown promise in preclinical studies, and this trial will provide critical data on its safety and efficacy in a clinical setting. The EMA clearance is a key regulatory milestone, enabling Lantern to expand its clinical development program into Europe. The company's AI-driven strategy, powered by the RADR platform, allows for efficient patient selection and trial design, potentially accelerating the development timeline.
This development is important because it demonstrates the translation of Lantern's AI capabilities into tangible clinical progress. The company's focus on biomarker-guided patient selection aligns with the broader trend toward personalized medicine in oncology. Successful results could position LP-184 as a new treatment option for bladder cancer patients with limited alternatives.
Lantern Pharma also operates a wholly owned CNS-focused subsidiary, Starlight Therapeutics, which is developing LP-184 for pediatric CNS cancers. Additionally, the company recently launched withZeta.ai, a multi-agentic AI co-scientist platform, now commercially available as a subscription-based research platform. This represents a new revenue stream and underscores Lantern's commitment to AI-driven drug development.
The trial at Rigshospitalet is expected to begin enrollment soon, and further updates will be provided as the study progresses. For more information, visit the company's newsroom at https://ibn.fm/LTRN.
